PRODUCTS PIPELINE ALPHA LIPOIC ACID 600MG TABLET (HVE - CHINA) Owned and developed by Health Vision Enterprise (HVE) in cooperation with Shanghai's renowned Jiao Tong University R&D centre, our formulation has been approved by SFDA for clinical trial and is expected to be launched in the China market by 2011. With 70% of diabetic patients being affected by diabetic poly neuropathy, this oral formulation will help penetrate the larger outpatient population. TIOTROPIUM BROMIDE INHALER (HVE - CHINA). A once daily, long acting anti cholinergic bronchodilator for the treatment of COPD. COPD is currently the fourth biggest killer in urban China, with 1million deaths per year and rising due to the increase in the smoking population. Our formulation is expected into the market by H1 2011. << Click here for more >>